Promotie onderzoek

OSIBOOST 2 is a clinical trial designed to enhance the cost-effectiveness of Osimertinib for patients with Non-Small Cell Lung Cancer (NSCLC). Although Osimertinib significantly improves progression-free survival compared to older EGFRm-targeted therapies, its high cost remains a concern. To address this, the trial investigates the use of the CYP3A4 inhibitor Cobicistat, which reduces the metabolism of Osimertinib and increases its exposure (a process known as pharmacokinetic boosting). This approach allows patients to take a lower dose of Osimertinib while achieving the same therapeutic effect, potentially making the treatment more affordable without compromising its efficacy.
 

To demonstrate abnormalities in antibiotic pharmacokinetics and consequently antibiotic exposure in critically ill patients
 

Het optimaliseren van de antivirale behandeling van kinderen met HIV in Afrika door verdieping in de PK/PD van deze middelen, nieuwe formuleringen en het voorspellen van de PK middels modelleren. 
 

To describe the impact of COVID-19 on the continuity of care in the primary care setting.
To describe the impact of delirium and frailty on clinical outcomes in COVID-19 patients admitted to the hospital.
To describe the impact of delirium on recovery of COVID-19 patients in geriatric rehabilitation.
To describe perceptions, motivations, needs and experiences of geriatricians with scientific research.
 

My research focuses on the socioeconomic determinants of psychotropic medication use in children and adolescents. Specifically, I aim to identify the complex relationships between socioeconomic factors and psychotropic medication use in young people, and to explore potential avenues for improving health outcomes in this vulnerable population.